Goldman Sachs’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-855,286
| Closed | -$958K | – | 6485 |
|
|
2025
Q2 | $958K | Buy |
855,286
+61,900
| +8% | +$75.6K | ﹤0.01% | 4741 |
|
|
2025
Q1 | $912K | Sell |
793,386
-185,099
| -19% | -$344K | ﹤0.01% | 4748 |
|
|
2024
Q4 | $5.98M | Sell |
978,485
-280,745
| -22% | -$3.34M | ﹤0.01% | 3277 |
|
|
2024
Q3 | $20.8M | Sell |
1,259,230
-74,683
| -6% | -$818K | ﹤0.01% | 2036 |
|
|
2024
Q2 | $9.16M | Buy |
1,333,913
+55,294
| +4% | +$473K | ﹤0.01% | 2579 |
|
|
2024
Q1 | $12.3M | Buy |
1,278,619
+238,110
| +23% | +$2.76M | ﹤0.01% | 2292 |
|
|
2023
Q4 | $8.65M | Buy |
1,040,509
+583,516
| +128% | +$3.39M | ﹤0.01% | 2666 |
|
|
2023
Q3 | $3.82M | Sell |
456,993
-215,196
| -32% | -$1.83M | ﹤0.01% | 3223 |
|
|
2023
Q2 | $6.2M | Buy |
672,189
+278,675
| +71% | +$3.12M | ﹤0.01% | 2913 |
|
|
2023
Q1 | $5.41M | Buy |
393,514
+194,588
| +98% | +$4.02M | ﹤0.01% | 2993 |
|
|
2022
Q4 | $3.38M | Sell |
198,926
-50,343
| -20% | -$1.01M | ﹤0.01% | 3511 |
|
|
2022
Q3 | $5.67M | Buy |
249,269
+50,715
| +26% | +$1.02M | ﹤0.01% | 3025 |
|
|
2022
Q2 | $3.58M | Sell |
198,554
-229,533
| -54% | -$4.09M | ﹤0.01% | 3505 |
|
|
2022
Q1 | $11.4M | Buy |
428,087
+24,463
| +6% | +$455K | ﹤0.01% | 2559 |
|
|
2021
Q4 | $11.8M | Sell |
403,624
-2,856
| -0.7% | -$142K | ﹤0.01% | 2605 |
|
|
2021
Q3 | $26.7M | Sell |
406,480
-16,403
| -4% | -$1.26M | 0.01% | 1787 |
|
|
2021
Q2 | $35.2M | Sell |
422,883
-317,427
| -43% | -$23.5M | 0.01% | 1562 |
|
|
2021
Q1 | $56.8M | Buy |
740,310
+534,992
| +261% | +$48.7M | 0.01% | 1075 |
|
|
2020
Q4 | $18.1M | Buy |
205,318
+145,264
| +242% | +$10.2M | ﹤0.01% | 1947 |
|
|
2020
Q3 | $4.43M | Sell |
60,054
-4,591
| -7% | -$272K | ﹤0.01% | 2997 |
|
|
2020
Q2 | $4.72M | Buy |
+64,645
| New | +$3.93M | ﹤0.01% | 2835 |
|
|
2019
Q4 | – | Sell |
-54,700
| Closed | -$971K | – | 5311 |
|
|
2019
Q3 | $971K | Buy |
+54,700
| New | +$1.1M | ﹤0.01% | 4049 |
|
Other funds holding IGMS
Goldman Sachs's IGMS Position: Q3 2025 in Review
Goldman Sachs sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 855,286 shares — an estimated $958K sold.
Goldman Sachs first reported a position in IGMS in Q3 2019 and held it in 22 quarters. The position peaked at $56.8M in Q1 2021. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- Goldman Sachs reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- Goldman Sachs sold 855,286 IGM Biosciences shares in Q3 2025, an estimated $958K.
- Goldman Sachs first reported a position in IGM Biosciences in Q3 2019 and held it in 22 quarters.
- Goldman Sachs's IGM Biosciences position peaked at $56.8M in Q1 2021.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.